Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03107078

Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial

Thyroid Associated Ophthalmopathy Clinical Trial

Official title:
Using A Novel Classification System in Intravenous Glucocorticoids Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial

Clinical Trial Summary

For patients with active moderate-to-severe thyroid associated ophthalmopathy (TAO), the Intravenous Glucocorticoids (GCs) is the recommended therapy. However, the efficacy of GCs is not satisfied. Investigators established a novel classification of TAO for the first time to assess more precisely for better personal treatment.

Clinical Trial Description

TAO is one of most common extra thyroid manifestation of dysfunctional thyroid disease. Since the morbidity of TAO has been increasing rapidly, Investigators' team is intended to verify the feasibility of the new type of classification system established by the related parameters of orbital MRI scan. Based on classification, investigators compare the efficacy of two GCs therapy. According to MRI,investigators measure the optimal T2 signal intensity ratio (SIR) for the treatment of TAO, which may help to find a better treatment time for therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03107078
Study type Interventional
Source The Third Affiliated Hospital of Southern Medical University
Contact Jie Shen, Doctor
Phone 13808893818
Email shenjiedr@163.com
Status Recruiting
Phase Phase 4
Start date October 1, 2016
Completion date October 1, 2021
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT06087731 - Efficacy and Safety of Tocilizumab for TAO Phase 2
Recruiting NCT05110040 - Multi-model Image of Immunosuppressive Agents in TAO N/A
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT04548284 - Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO Phase 3
Recruiting NCT03515863 - Natural History and Risk Factors of TAO
Not yet recruiting NCT06392906 - Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial) Phase 3
Recruiting NCT06226545 - A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease Phase 2
Completed NCT00150111 - Rituximab in the Treatment of Graves' Disease Phase 1/Phase 2
Completed NCT03110848 - Effects of Atorvastatin in Graves' Orbitopathy (GO) Phase 2
Recruiting NCT04662190 - Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery. N/A
Recruiting NCT05276063 - A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Not yet recruiting NCT04919694 - Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy N/A
Recruiting NCT03131726 - Treatment of Graves´Ophthalmopathy With Simvastatin (GO-S) Phase 3
Completed NCT02766660 - Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy N/A
Active, not recruiting NCT06269393 - A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy Phase 3
Not yet recruiting NCT03098225 - A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Phase 4
Recruiting NCT05112211 - Multi-model Image of Doxycycline in TAO N/A